AR078358A1 - Uso de derivados de indol como activadores de nurr-1 para la aplicacion como un producto medicinal destinado al tratamiento de la enfermedad de parkinson - Google Patents
Uso de derivados de indol como activadores de nurr-1 para la aplicacion como un producto medicinal destinado al tratamiento de la enfermedad de parkinsonInfo
- Publication number
- AR078358A1 AR078358A1 ARP100103313A ARP100103313A AR078358A1 AR 078358 A1 AR078358 A1 AR 078358A1 AR P100103313 A ARP100103313 A AR P100103313A AR P100103313 A ARP100103313 A AR P100103313A AR 078358 A1 AR078358 A1 AR 078358A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- carbon atoms
- groups
- hydrogen atom
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/26—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an acyl radical attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Abstract
El uso de derivados de indol como activadores de NURR-1, para la aplicacion como un producto medicinal destinado al tratamiento de la enfermedad de Parkinson. Se aplica en el campo farmacéutico, para el tratamiento de enfermedades neurodegenerativas y, en particular, para el tratamiento de la enfermedad de Parkinson. Reivindicacion 1: Un compuesto caracterizado porque se selecciona entre: i) los compuestos de la formula: (1) en la cual: Cy representa un grupo fenilo o un grupo heteroaromático, que tiene 5 o 6 miembros en el anillo; R1 y R2, cada uno de ellos, independientemente uno del otro, representa, un átomo de hidrogeno, un átomo de halogeno, un grupo nitro, un grupo alquilo que tiene de 1 a 4 átomos de carbono, opcionalmente, halogenados en forma total o parcial, un grupo alcoxi que tiene de 1 a 4 átomos de carbono, un grupo heterocíclico que tiene de 4 a 6 átomos, un grupo -SCH3, OCF3, -NH2, -NHR o -NR2; R3 y R4, cada uno de ellos, independientemente uno del otro, representa, un átomo de hidrogeno, un átomo de halogeno, un grupo alquilo que tiene de 1 a 4 átomos de carbono, un grupo hidroxilo o un grupo alcoxi que tiene de 1 a 4 átomos de carbono; R5 y R6, cada uno de ellos, independientemente uno del otro, representa, un átomo de hidrogeno, un átomo de halogeno, un grupo alquilo que tiene de 1 a 4 átomos de carbono, un grupo hidroxilo; o R5 y R6 forman, junto con el átomo de carbono al cual están unidos, un grupo cicloalquilo que tiene de 3 a 6 átomos de carbono, un grupo etileno (C=CH2) o un grupo carbonilo (C=O); R7 representa un grupo -COOR, un grupo bioisostérico de ácido carboxílico o un grupo -CN; R8 representa: un grupo alquilo que tiene de 1 a 6 átomos de carbono, un grupo arilo, heteroarilo, cíclico o heterocíclico, grupo que está insustituido o sustituido con uno, dos o tres sustituyentes que pueden ser idénticos o diferentes, seleccionados entre átomos de halogeno, grupos alquilo que tienen de 1 a 6 átomos de carbono, opcionalmente, halogenados en forma total o parcial u opcionalmente, grupos alcoxi hidroxilados, que tienen de 1 a 6 átomos de carbono, opcionalmente, halogenados en forma total o parcial, donde el grupo fenoxi, los grupos cíclicos que tienen de 3 a 6 átomos de carbono, los grupos arilo y heteroarilo, en particular fenilo y pirazolilo, insustituidos o sustituidos con uno o dos sustituyentes, que pueden ser idénticos o diferentes, seleccionados entre átomos de halogeno y grupos alquilo que tienen de 1 a 4 átomos de carbono, los grupos SCHF2 y acil-morfolino; R9 representa un átomo de hidrogeno, un átomo de halogeno o un grupo alquilo que tiene de 1 a 4 átomos de carbono; R representa un átomo de hidrogeno o un grupo alquilo lineal o ramificado, que tiene de 1 a 4 átomos de carbono; ii) las sales farmacéuticamente aceptables de dichos compuestos de la formula (1); para usar como una sustancia terapéuticamente activa.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0956259A FR2950053B1 (fr) | 2009-09-11 | 2009-09-11 | Utilisation de derives d'indole benzoique comme activateurs de nurr-1, pour le traitement de la maladie de parkinson |
FR1050107A FR2950058B1 (fr) | 2009-09-11 | 2010-01-08 | Utilisation de derives d'indole benzoique comme activateurs de nurr-1, pour le traitement de la maladie de parkinson |
Publications (1)
Publication Number | Publication Date |
---|---|
AR078358A1 true AR078358A1 (es) | 2011-11-02 |
Family
ID=42061922
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP100103313A AR078358A1 (es) | 2009-09-11 | 2010-09-10 | Uso de derivados de indol como activadores de nurr-1 para la aplicacion como un producto medicinal destinado al tratamiento de la enfermedad de parkinson |
Country Status (26)
Country | Link |
---|---|
US (1) | US20120232070A1 (es) |
EP (1) | EP2475642A1 (es) |
JP (1) | JP2013504548A (es) |
KR (1) | KR20120065345A (es) |
CN (2) | CN103554006A (es) |
AR (1) | AR078358A1 (es) |
AU (1) | AU2010294018A1 (es) |
BR (1) | BR112012005480A2 (es) |
CA (1) | CA2772697A1 (es) |
CL (1) | CL2012000632A1 (es) |
CO (1) | CO6511224A2 (es) |
CR (1) | CR20120131A (es) |
DO (1) | DOP2012000061A (es) |
EC (1) | ECSP12011718A (es) |
FR (2) | FR2950053B1 (es) |
IL (1) | IL218526A0 (es) |
IN (1) | IN2012DN02005A (es) |
MX (1) | MX2012003027A (es) |
NZ (1) | NZ598576A (es) |
PE (1) | PE20121346A1 (es) |
RU (1) | RU2012110883A (es) |
SA (1) | SA110310698B1 (es) |
SG (1) | SG178451A1 (es) |
TW (1) | TW201119650A (es) |
WO (1) | WO2011030068A1 (es) |
ZA (1) | ZA201201400B (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105272975B (zh) * | 2014-06-10 | 2019-03-26 | 中国科学院上海药物研究所 | 一类具有1,2,4-恶二唑片段结构的吲哚生物碱及其制备方法和用途 |
WO2018136575A1 (en) * | 2017-01-18 | 2018-07-26 | Albert Einstein College Of Medicine, Inc. | Pxr agonists and uses thereof for gut barrier dysfunction treatment and prevention |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9615441D0 (en) * | 1996-07-23 | 1996-09-04 | Pharmacia Spa | Benzoylpropionic acid ester derivatives |
GB9716656D0 (en) | 1997-08-07 | 1997-10-15 | Zeneca Ltd | Chemical compounds |
EP1086950B1 (en) * | 1998-05-26 | 2010-09-29 | Chugai Seiyaku Kabushiki Kaisha | Heterocyclic indole derivatives and mono- or diazaindole derivatives |
GB9902461D0 (en) | 1999-02-05 | 1999-03-24 | Zeneca Ltd | Chemical compounds |
NZ522246A (en) * | 2000-04-28 | 2006-01-27 | Baxter Healthcare Sa | 2-acyl indole derivatives and their use as antitumor agents |
GB0119911D0 (en) | 2001-08-15 | 2001-10-10 | Novartis Ag | Organic Compounds |
GB0303503D0 (en) | 2003-02-14 | 2003-03-19 | Novartis Ag | Organic compounds |
AR043633A1 (es) * | 2003-03-20 | 2005-08-03 | Schering Corp | Ligandos de receptores de canabinoides |
WO2004108094A2 (en) * | 2003-06-06 | 2004-12-16 | Atherogenics, Inc. | Sulfonamide-substituted chalcone derivatives and their use to treat diseases |
WO2005047268A2 (en) | 2003-11-10 | 2005-05-26 | X-Ceptor Therapeutics, Inc. | Substituted pyrimidine compositions and methods of use |
WO2005056522A2 (en) | 2003-12-04 | 2005-06-23 | National Health Research Institutes | Indole compounds |
AU2005254658B2 (en) * | 2004-06-21 | 2011-06-16 | F. Hoffmann-La Roche Ag | Indole derivatives as histamine receptor antagonists |
FR2890071B1 (fr) * | 2005-08-30 | 2007-11-09 | Fournier Sa Sa Lab | Nouveaux composes de l'indole |
US20070072904A1 (en) * | 2005-09-07 | 2007-03-29 | Jack Lin | PPAR active compounds |
FR2903106B1 (fr) | 2006-07-03 | 2010-07-30 | Sanofi Aventis | Utilisations de 2-benzoyl-imidazopyridines en therapeutique |
FR2903107B1 (fr) | 2006-07-03 | 2008-08-22 | Sanofi Aventis Sa | Derives d'imidazopyridine-2-carboxamides, leur preparation et leur application en therapeutique |
FR2903105A1 (fr) | 2006-07-03 | 2008-01-04 | Sanofi Aventis Sa | Derives de 2-benzoyl-imidazopyridines, leur preparation et leur application en therapeutique |
-
2009
- 2009-09-11 FR FR0956259A patent/FR2950053B1/fr active Active
-
2010
- 2010-01-08 FR FR1050107A patent/FR2950058B1/fr active Active
- 2010-09-10 WO PCT/FR2010/051884 patent/WO2011030068A1/fr active Application Filing
- 2010-09-10 AU AU2010294018A patent/AU2010294018A1/en not_active Abandoned
- 2010-09-10 IN IN2005DEN2012 patent/IN2012DN02005A/en unknown
- 2010-09-10 EP EP10770545A patent/EP2475642A1/fr not_active Withdrawn
- 2010-09-10 CN CN201310415421.6A patent/CN103554006A/zh active Pending
- 2010-09-10 JP JP2012528430A patent/JP2013504548A/ja active Pending
- 2010-09-10 CN CN2010800509223A patent/CN102596906A/zh active Pending
- 2010-09-10 AR ARP100103313A patent/AR078358A1/es unknown
- 2010-09-10 BR BR112012005480A patent/BR112012005480A2/pt not_active IP Right Cessation
- 2010-09-10 KR KR1020127006186A patent/KR20120065345A/ko not_active Application Discontinuation
- 2010-09-10 TW TW099130733A patent/TW201119650A/zh unknown
- 2010-09-10 CA CA2772697A patent/CA2772697A1/fr not_active Abandoned
- 2010-09-10 RU RU2012110883/04A patent/RU2012110883A/ru not_active Application Discontinuation
- 2010-09-10 MX MX2012003027A patent/MX2012003027A/es not_active Application Discontinuation
- 2010-09-10 SG SG2012010815A patent/SG178451A1/en unknown
- 2010-09-10 PE PE2012000304A patent/PE20121346A1/es not_active Application Discontinuation
- 2010-09-10 NZ NZ598576A patent/NZ598576A/en not_active IP Right Cessation
- 2010-09-18 SA SA110310698A patent/SA110310698B1/ar unknown
-
2012
- 2012-02-24 ZA ZA2012/01400A patent/ZA201201400B/en unknown
- 2012-03-03 EC ECSP12011718 patent/ECSP12011718A/es unknown
- 2012-03-07 DO DO2012000061A patent/DOP2012000061A/es unknown
- 2012-03-07 IL IL218526A patent/IL218526A0/en unknown
- 2012-03-09 CL CL2012000632A patent/CL2012000632A1/es unknown
- 2012-03-09 CO CO12041658A patent/CO6511224A2/es not_active Application Discontinuation
- 2012-03-09 US US13/416,018 patent/US20120232070A1/en not_active Abandoned
- 2012-03-19 CR CR20120131A patent/CR20120131A/es unknown
Also Published As
Publication number | Publication date |
---|---|
IN2012DN02005A (es) | 2015-07-24 |
ZA201201400B (en) | 2013-05-29 |
FR2950058A1 (fr) | 2011-03-18 |
SA110310698B1 (ar) | 2014-11-16 |
KR20120065345A (ko) | 2012-06-20 |
US20120232070A1 (en) | 2012-09-13 |
FR2950053B1 (fr) | 2014-08-01 |
FR2950053A1 (fr) | 2011-03-18 |
DOP2012000061A (es) | 2012-09-30 |
CN103554006A (zh) | 2014-02-05 |
TW201119650A (en) | 2011-06-16 |
NZ598576A (en) | 2014-05-30 |
AU2010294018A1 (en) | 2012-03-29 |
JP2013504548A (ja) | 2013-02-07 |
ECSP12011718A (es) | 2012-04-30 |
MX2012003027A (es) | 2012-04-19 |
RU2012110883A (ru) | 2013-10-20 |
EP2475642A1 (fr) | 2012-07-18 |
CA2772697A1 (fr) | 2011-03-17 |
PE20121346A1 (es) | 2012-10-15 |
CR20120131A (es) | 2012-07-27 |
BR112012005480A2 (pt) | 2019-09-24 |
IL218526A0 (en) | 2012-07-31 |
SG178451A1 (en) | 2012-03-29 |
WO2011030068A1 (fr) | 2011-03-17 |
CL2012000632A1 (es) | 2012-10-19 |
FR2950058B1 (fr) | 2016-04-01 |
CN102596906A (zh) | 2012-07-18 |
CO6511224A2 (es) | 2012-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1122610T1 (el) | Αλκοξυ πυραζολια ως ενεργοποιητες διαλυτης γουανυλικης κυκλασης | |
AR119698A2 (es) | Compuesto amida n-urea sustituida derivado de aminoácido | |
CY1118973T1 (el) | Παραγωγα αμιδιου βενζοϊμιδαζολο-καρβοξυλικου οξεος για τη θεραπεια μεταβολικων ή καρδιαγγειακων νοσηματων | |
AR072227A1 (es) | Derivados de triazinona sustituidos | |
AR087915A1 (es) | N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1 | |
AR070558A1 (es) | Derivados de 7-fenil-7h-pirrolo-[2,3d]-pirimidin-2-il-amino,proceso para prepararlos, composiciones farmaceuticas que los comprenden y uso de los mismos para el tratamiento de enfermedades dependientes de tirosinquinasas,tales como enfermedades proliferativas. | |
CY1119423T1 (el) | Παραγωγο κυκλοαλκυλ-υποκατεστημενης ιμιδαζολης | |
JP2014511892A5 (es) | ||
AR079327A1 (es) | Derivados de 2-amino-5,5-difluor -5,6-dihidro-4h-(1,3) oxazin-4-il) fenil)-amida | |
AR083849A1 (es) | Antagonistas de mdm2 de espiro-oxindol | |
AR060604A1 (es) | Nuevos arilamino n- heteroarilos como inhibidores de mek | |
CY1119118T1 (el) | Θεραπευτικος παραγων για τις διαταραχες της διαθεσης | |
PE20141405A1 (es) | Nuevos derivados de indolizina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
AR079164A1 (es) | Derivados heterociclicos de indol, composiciones farmaceuticas que los comprenden y uso de los mismos para la profilaxis o tratamiento de enfermedades alergicas, inflamatorias y/o autoinmunes. | |
CR20140399A (es) | Pirrolidina-2-carboxamidas sustituidas | |
AR067646A1 (es) | Ariloxazoles sustituidos y su uso | |
UY36226A (es) | Ácidos carboxílicos heterocíclicos como activadores de guanilato ciclasa soluble | |
PE20141352A1 (es) | Fenil-3-aza-biciclo[3,1,0]hex-3-il-metanonas y su uso como medicamento | |
AR057906A1 (es) | Derivados de pirimidona biciclicos sustituidos y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la actividad anormal de gsk3beta. | |
CO7280475A2 (es) | Derivados de azaindol que actuan como inhibidores de pi3k | |
AR045113A1 (es) | Derivados sustituidos del dioxido de tiazolbenzoisotiazol, procedimiento para su preparacion y su uso | |
UY35551A (es) | Derivados heteroarilos como inhibidores de aldosterona sintasa | |
PE20141000A1 (es) | Ureas asimetricas y usos medicos de las mismas | |
UY33191A (es) | Derivados de pirazina | |
AR075534A1 (es) | Derivados de piridazinona sustituida por heteroarilo |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |